LogicBio Therapeutics - LOGC Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LOGC shares.
View LOGC analyst ratings or view top-rated stocks.

2 brokerages have issued 1-year price objectives for LogicBio Therapeutics' shares. Their LOGC share price forecasts range from $2.50 to $2.50. On average, they expect the company's share price to reach $2.50 in the next year. This suggests a possible upside of 20.8% from the stock's current price.
View analysts price targets for LOGC or view top-rated stocks among Wall Street analysts.

LogicBio Therapeutics' stock was trading at $2.31 at the beginning of 2022. Since then, LOGC shares have decreased by 10.4% and is now trading at $2.07.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, March 3rd 2023.
View our LOGC earnings forecast.

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. The firm had revenue of $2.12 million for the quarter, compared to analyst estimates of $5.02 million. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 115.29% and a negative net margin of 246.71%.

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

(LOGC) raised $77 million in an initial public offering on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

LogicBio Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.52%), Renaissance Technologies LLC (0.86%), Citadel Advisors LLC (0.35%) and Prudential Financial Inc. (0.30%). Insiders that own company stock include Bioscience Plc Arix, Daniel Gruskin, Frederic Chereau, Kyle Chiang and Orbimed Advisors Llc.
View institutional ownership trends.

Shares of LOGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LOGC stock can currently be purchased for approximately $2.07.

LogicBio Therapeutics (NASDAQ:LOGC) has a market capitalization of $68.23 million and generates $5.41 million in revenue each year. The company earns $-40,030,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The official website for the company is www.logicbio.com. The company can be reached via phone at (617) 245-0399 or via email at michael@sternir.com.